Valuation: Alkermes plc

Market Cap 810.8Cr 694.53Cr 649.86Cr 594.87Cr 1.12TCr 78TCr 1.13TCr 7.68TCr 2.99TCr 39TCr 3.04TCr 2.98TCr 1,28900Cr P/E 2026 *
-94.7x
P/E 2027 * 66.5x
Enterprise Value 885.19Cr 758.26Cr 709.48Cr 649.45Cr 1.22TCr 85TCr 1.23TCr 8.38TCr 3.27TCr 43TCr 3.32TCr 3.25TCr 1,40700Cr EV / Sales 2026 *
4.85x
EV / Sales 2027 * 4.51x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week-1.49%
Current month-1.35%
1 month-8.55%
3 months+30.80%
6 months+51.46%
Current year+72.73%
1 week 47.33
Extreme 47.33
51.29
1 month 47.33
Extreme 47.33
53.88
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

Executive/Senior Manager

-7,576 0.0045%
05/08/26 Free

Chief Executive Officer

2,17,534 0.1297%
03/08/26 Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%-1.49%+66.31%+63.06% 810.8Cr
+1.09%+5.26%+4.44%+26.03% 5.16TCr
-1.07%+2.82%+474.18%+601.24% 4.49TCr
+1.47%+9.79%+40.15%+21.21% 4.28TCr
+1.44%+7.77%+19.27%+90.94% 4.26TCr
-0.93%-4.33%+17.87%+51.96% 3.18TCr
+1.32%+7.30%+36.93%+152.36% 1.73TCr
-0.60%+1.93% - - 1.66TCr
+0.03%+3.41%+7.12%+35.49% 1.48TCr
+1.28%+5.41%+91.01%+46.93% 1.41TCr
Average +0.47%+3.84%+84.14%+121.02% 2.85TCr
Weighted average by Cap. +0.49%+4.54%+101.47%+145.94%

Financials

2026 *2027 *
Net sales 182.49Cr 156.32Cr 146.27Cr 133.89Cr 251.27Cr 17TCr 254.59Cr 1.73TCr 673.9Cr 8.77TCr 685.24Cr 670.33Cr 29TCr 194.48Cr 166.6Cr 155.88Cr 142.69Cr 267.79Cr 19TCr 271.33Cr 1.84TCr 718.19Cr 9.35TCr 730.27Cr 714.38Cr 31TCr
Net income -8.99Cr -7.7Cr -7.21Cr -6.6Cr -12Cr -860.34Cr -13Cr -85Cr -33Cr -432.19Cr -34Cr -33Cr -1.43TCr 12Cr 10Cr 9.64Cr 8.83Cr 17Cr 1.15TCr 17Cr 113.91Cr 44Cr 578.15Cr 45Cr 44Cr 1.91TCr
Net Debt 74Cr 64Cr 60Cr 55Cr 102.43Cr 7.12TCr 103.78Cr 704.45Cr 274.71Cr 3.58TCr 279.33Cr 273.26Cr 12TCr 67Cr 57Cr 54Cr 49Cr 92Cr 6.41TCr 93Cr 634.38Cr 247.39Cr 3.22TCr 251.55Cr 246.08Cr 11TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
21/26/21 $48.33 +0.65% 9,39,635
20/26/20 $48.02 -4.30% 16,35,207
19/26/19 $50.18 +1.41% 15,44,219
18/26/18 $49.48 -0.74% 9,70,918
17/26/17 $49.85 +1.61% 7,64,040
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
48.33USD
Average target price
56.00USD
Spread / Average Target
+15.87%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock